Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Xu Yu, M.D.

Co-Author

This page shows the publications co-authored by Xu Yu and Todd Allen.
Connection Strength

0.726
  1. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J Virol. 2008 Jun; 82(11):5594-605.
    View in: PubMed
    Score: 0.098
  2. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med. 2007 Nov 26; 204(12):2813-24.
    View in: PubMed
    Score: 0.096
  3. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes. J Virol. 2007 Feb; 81(4):1619-31.
    View in: PubMed
    Score: 0.090
  4. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol. 2005 Oct; 79(20):12952-60.
    View in: PubMed
    Score: 0.083
  5. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol. 2004 Jul; 78(13):7069-78.
    View in: PubMed
    Score: 0.076
  6. Differences in the expressed HLA class I alleles effect the differential clustering of HIV type 1-specific T cell responses in infected Chinese and caucasians. AIDS Res Hum Retroviruses. 2004 May; 20(5):557-64.
    View in: PubMed
    Score: 0.075
  7. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol. 2012 Jun 10; 13(7):691-700.
    View in: PubMed
    Score: 0.033
  8. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol. 2007 Apr; 81(8):4199-214.
    View in: PubMed
    Score: 0.023
  9. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med. 2006 Oct; 3(10):e403.
    View in: PubMed
    Score: 0.022
  10. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol. 2005 Jun 15; 174(12):7524-30.
    View in: PubMed
    Score: 0.020
  11. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design. J Virol. 2005 Apr; 79(8):5000-5.
    View in: PubMed
    Score: 0.020
  12. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS. 2004 Jul 02; 18(10):1383-92.
    View in: PubMed
    Score: 0.019
  13. HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. Blood. 2004 Jul 15; 104(2):487-94.
    View in: PubMed
    Score: 0.019
  14. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS. 2003 Dec 05; 17(18):2581-91.
    View in: PubMed
    Score: 0.018
  15. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol. 2003 Jul; 77(13):7330-40.
    View in: PubMed
    Score: 0.018
  16. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature. 2002 Nov 28; 420(6914):434-9.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.